ES2592283T3 - 13,14-Dihidro-15-ceto-16,16-difluoro-prostaglandina E1 o 13,14-dihidro-15-ceto-16,16-difluoro-18-metil-prostaglandina E1 para el tratamiento de una enfermedad intestinal inflamatoria - Google Patents

13,14-Dihidro-15-ceto-16,16-difluoro-prostaglandina E1 o 13,14-dihidro-15-ceto-16,16-difluoro-18-metil-prostaglandina E1 para el tratamiento de una enfermedad intestinal inflamatoria Download PDF

Info

Publication number
ES2592283T3
ES2592283T3 ES11170933.3T ES11170933T ES2592283T3 ES 2592283 T3 ES2592283 T3 ES 2592283T3 ES 11170933 T ES11170933 T ES 11170933T ES 2592283 T3 ES2592283 T3 ES 2592283T3
Authority
ES
Spain
Prior art keywords
prostaglandin
keto
difluoro
dihydro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES11170933.3T
Other languages
English (en)
Spanish (es)
Inventor
Ryuji Ueno
Sachiko Kuno
Anthony T. Blikslager
Adam J. Moeser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
North Carolina State University
Original Assignee
Sucampo GmbH
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH, North Carolina State University filed Critical Sucampo GmbH
Application granted granted Critical
Publication of ES2592283T3 publication Critical patent/ES2592283T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES11170933.3T 2005-03-21 2006-03-22 13,14-Dihidro-15-ceto-16,16-difluoro-prostaglandina E1 o 13,14-dihidro-15-ceto-16,16-difluoro-18-metil-prostaglandina E1 para el tratamiento de una enfermedad intestinal inflamatoria Expired - Lifetime ES2592283T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US66320005P 2005-03-21 2005-03-21
US663200P 2005-03-21
US67992005P 2005-05-11 2005-05-11
US679920P 2005-05-11
US72197605P 2005-09-30 2005-09-30
US721976P 2005-09-30

Publications (1)

Publication Number Publication Date
ES2592283T3 true ES2592283T3 (es) 2016-11-29

Family

ID=36754577

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11170933.3T Expired - Lifetime ES2592283T3 (es) 2005-03-21 2006-03-22 13,14-Dihidro-15-ceto-16,16-difluoro-prostaglandina E1 o 13,14-dihidro-15-ceto-16,16-difluoro-18-metil-prostaglandina E1 para el tratamiento de una enfermedad intestinal inflamatoria

Country Status (14)

Country Link
US (1) US20060281818A1 (enExample)
EP (3) EP2384790A3 (enExample)
JP (2) JP5219797B2 (enExample)
KR (2) KR101456298B1 (enExample)
CN (1) CN103948603A (enExample)
AU (1) AU2006225515B2 (enExample)
BR (1) BRPI0609672A2 (enExample)
CA (2) CA2601158C (enExample)
ES (1) ES2592283T3 (enExample)
IL (1) IL185861A (enExample)
MX (1) MX2007011645A (enExample)
NO (1) NO20075361L (enExample)
NZ (3) NZ597857A (enExample)
WO (1) WO2006101244A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
CN101918017B (zh) * 2007-10-25 2013-07-31 植物药学公司 Phy906用于治疗炎性肠病和/或肠易激综合征的用途
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US20100305203A1 (en) * 2009-05-27 2010-12-02 Sucampo Ag Method for modulating claudin mediated functions
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
AU2012246999A1 (en) * 2011-04-19 2013-10-17 Sucampo Ag Method for modulating cytokine activity
JP2014515004A (ja) * 2011-04-27 2014-06-26 スキャンポ・アーゲー イオン輸送体の調節方法
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
US20160120840A1 (en) * 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease
EP3292135B1 (en) * 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
WO2024217532A1 (zh) * 2023-04-20 2024-10-24 中南大学湘雅二医院 Carboprost在制备抗肿瘤药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPS58216155A (ja) * 1982-06-10 1983-12-15 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
JPS591463A (ja) * 1982-06-28 1984-01-06 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
FR2608924B1 (fr) * 1986-12-29 1990-07-20 Pasteur Institut Compositions therapeutiques contenant des derives soufres de prostaglandines, nouveaux derives soufres et leur procede de preparation
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) * 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5234858A (en) 1990-11-16 1993-08-10 Micron Technology, Inc. Stacked surrounding wall capacitor
KR940007277B1 (ko) 1992-02-14 1994-08-12 한국과학기술원 2차 전지 전극용 수소 저장 합금
US5376034A (en) 1992-05-27 1994-12-27 Brunswick Corporation Marine drive exhaust system
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
US5876034A (en) 1997-12-17 1999-03-02 Stafford; James R. Sporting fishing board game
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
GB2375349A (en) * 2001-02-13 2002-11-13 Glaxo Group Ltd Chloride intracellular channel-related proteins
US6919082B2 (en) * 2001-02-13 2005-07-19 Kirin Beer Kabushiki Kaisha Pharmacological composition containing yeast cell wall fraction
GB0111497D0 (en) * 2001-05-11 2001-07-04 Medical Res Council Therapeutic methods
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
JP4889219B2 (ja) * 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
WO2006047476A2 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders

Also Published As

Publication number Publication date
KR20140072102A (ko) 2014-06-12
CA2601158A1 (en) 2006-09-28
EP2384790A2 (en) 2011-11-09
BRPI0609672A2 (pt) 2010-04-20
IL185861A (en) 2015-06-30
EP1861169A2 (en) 2007-12-05
AU2006225515A1 (en) 2006-09-28
NZ597857A (en) 2013-08-30
AU2006225515A8 (en) 2006-09-28
EP2384791A3 (en) 2011-12-28
KR20080012266A (ko) 2008-02-11
US20060281818A1 (en) 2006-12-14
WO2006101244A2 (en) 2006-09-28
CA2831416C (en) 2016-12-13
EP2384791A2 (en) 2011-11-09
KR101456298B1 (ko) 2014-11-03
CN103948603A (zh) 2014-07-30
AU2006225515B2 (en) 2012-02-02
NZ562351A (en) 2010-12-24
CA2601158C (en) 2015-10-13
IL185861A0 (en) 2008-01-06
JP2012180380A (ja) 2012-09-20
EP1861169B1 (en) 2016-05-11
JP5219797B2 (ja) 2013-06-26
JP5777574B2 (ja) 2015-09-09
JP2008533195A (ja) 2008-08-21
NO20075361L (no) 2007-12-20
NZ588878A (en) 2012-05-25
CA2831416A1 (en) 2006-09-28
WO2006101244A3 (en) 2007-02-08
EP2384791B1 (en) 2016-06-15
EP2384790A3 (en) 2011-12-28
MX2007011645A (es) 2007-11-16

Similar Documents

Publication Publication Date Title
Codaccioni et al. Sevoflurane preconditioning against focal cerebral ischemia: inhibition of apoptosis in the face of transient improvement of neurological outcome
Gellai et al. Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670.
Tomlinson et al. Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia
Worcester et al. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I
Sonnenberg et al. When is esophagitis healed? Esophageal endoscopy, histology and function before and after cimetidine treatment
Söderholm et al. Bone scanning for evaluating mandibular bone extension of oral squamous cell carcinoma
PT1007566E (pt) Utilização terapêutica da proteína smrl e seus derivados activos
Rose et al. Post-ejection wall thickening as a marker of successful short term hibernation
Ginès et al. Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites: effect of increasing systemic arterial pressure
US20230241159A1 (en) Peptide Having Mesenchymal Stem Cell Mobilizing Activity
Lormeau et al. Adrenocorticotropin-producing pituitary carcinoma with liver metastasis
KR102599293B1 (ko) 암의 조기 골 전이의 화상 진단제
Skrabal et al. Subtraction potential difference: In-vivo assay for mineralocorticoid activity
Pawlik et al. Effects of peripherally and centrally applied ghrelin in the pathogenesis of ischemia-reperfusion induced injury of the small intestine
Guslandi et al. Gastric microcirculation and bicarbonate production in heavy smokers
Resch et al. Glycyl-l-glutamine antagonizes α-MSH-elicited thermogenesis
Asko-Seljavaara Kidney tubular cell proliferation in burned mice
Blumenfrucht et al. Multiorgan crystal deposition following intravenous oxalate infusion in rat
Anthone et al. Neuropeptide Y is a proabsorptive agent in the small intestine
Araujo et al. Intramastoid Phosphaturic Mesenchymal Tumor Causing Hypophosphatemic Osteomalacia Detected on 68Ga-DOTATATE PET/CT But Not on 99mTc-Sestamibi and 18F-FDG Scans
Nakamura et al. Acute and long-term effects of vagotomy on gastric mucosal blood flow
Scremin et al. Pathogenesis of duodenal ulcer in the rat: dissociation of acid load and blood flow
Srivastava et al. Juvenile rheumatoid arthritis with amyloid goiter: report of a case with review of the literature
Huang et al. Normal values for parotid gland and submandibular-sublingual salivary gland complex uptake of 99mtechnetium pertechnetate using SPECT in mice with respect to age, sex, and circadian rhythm
Goerg et al. Rhein stimulates active chloride secretion in the short-circuited rat colonic mucosa